In a recent New England Journal of Medicine issue (see link) a study of obese patients with type 2 diabetes treated via medical therapy alone versus medical therapy combined with Roux-en-Y gastric bypass or sleeve gastrectomy revealed that either gastric bypass or gastrectomy combined with medical therapy is associated with lower glycated hemoglobin (better glycemic control) than those treated with medical therapy alone. The best results were found with medical therapy combined with gastric bypass. Moreover, it was found that use of drugs to manage the type 2 diabetes declined in patients who underwent gastric bypass or sleeve gastrectomy, but actually increased in patients who underwent medical therapy alone.
Treatment of diabetes in type 2 diabetics who are also obese by addressing obesity has previously shown that a direct, positive correlation exists between reduction in obesity and improved diabetes management.
Obesity's known comorbidity with hypertension, dyslipidemia, cardiovascular disease and other conditions, as well as with the common vascular complications of diabetes (retinopathy, neuropathy, and nephropathy) make it fairly clear that there is a cascade of benefits to be derived from pursuing treatment of obesity. The NEJM study further underscores this, lending support to the fact that nearly all types of treatments — drug or device — for obesity are demonstrating double digit growth and will continue to do so until prevalences dramatically decline. (See link.)
Americas Market for Treatment of Obesity, 2009-2019 (USD Millions)
Source: "Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019", Report #S835; MedMarket Diligence, LLC.